Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 11/03/21
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021GlobeNewsWire • 10/27/21
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product PortfolioGlobeNewsWire • 10/11/21
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDAGlobeNewsWire • 09/02/21
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Supernus Pharmaceuticals (SUPN) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/04/21
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising InvestmentSeeking Alpha • 06/02/21
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of AgeGlobeNewsWire • 05/24/21
Supernus Pharmaceuticals: Virtuous Cycle Of Free Cash Flow Generation To Fund Product Development And AcquisitionSeeking Alpha • 05/13/21
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss EstimatesZacks Investment Research • 05/05/21